Skip to content

Twitter page opens in new window Linkedin page opens in new window Instagram page opens in new window

info@pharmaust.com+61 8 9202 6814

PharmAust (PAA)

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

30 April, Top 20 Shareholders

Top_Holders_Report (2)

Categories: News & Announcements 2019, Top 20 ShareholdersBy PharmAust May 6, 2019

Related posts

May 31, Top 20 Shareholders
June 1, 2020

April 30, Top 20 Shareholders
April 30, 2020

31 March, Top 20 Shareholders
March 31, 2020

29 February, Top 20 Shareholders
February 29, 2020

31 December, Top 20 Shareholders
December 31, 2019

Expanded Site Recruitment for Monepantel Phase II Trial in Pet Dogs with Cancer
December 11, 2019

Recent Articles

4 June, Preliminary Monepantel SARS-CoV-2 Data
June 4, 2020
May 31, Top 20 Shareholders
June 1, 2020
PAA Research Report May 2020
May 28, 2020
12 May, Phase II Trial – Successful Anti-Cancer Outcome
May 12, 2020

MENU

Home
About Us
Pipeline & Trials
Investor Centre
Media
Contact Us

SUBSCRIBE TO OUR NEWSLETTER

Leave this field empty if you're human:

TWITTER

PharmAustFollow

PharmAust is a clinical-stage company developing novel targeted cancer therapeutics for both humans and animals. ASX: $PAA

Retweet on Twitter PharmAust Retweeted

BioTuesdays @BioTuesdays·

.@PharmAust posted positive preliminary results in experiments aimed at inhibiting the virus that causes COVID-19 https://biotuesdays.com/2020/06/04/pharmaust-lab-tests-show-positive-signs-for-suppressing-covid-19/

Reply on Twitter 1268552094262480897 Retweet on Twitter 12685520942624808972 Like on Twitter 12685520942624808972 Twitter 1268552094262480897

Copyright © 2020 Pharmaust. All rights reserved.

Website Design & Digital Marketing Perth by Total Click Solutions